Literature DB >> 18539500

Inhalation of Francisella novicida Delta mglA causes replicative infection that elicits innate and adaptive responses but is not protective against invasive pneumonic tularemia.

T Eoin West1, Mark R Pelletier, Melanie C Majure, Annalisa Lembo, Adeline M Hajjar, Shawn J Skerrett.   

Abstract

Francisella tularensis causes the zoonosis tularemia in humans, and inhaled F. tularensis ssp. novicida induces lethal murine tularemia. Transcription of virulence factors in F. novicida is regulated by macrophage growth locus A (mglA), a global regulator required for bacterial replication in macrophages in vitro. We examined the infectivity and immunogenicity of attenuated F. novicida Delta mglA in the lung in vivo. Aerosolized Delta mglA caused replicative pulmonary infection that peaked at 7 days and was cleared thereafter, without clinical evidence of disease. In contrast, inhalation of wild type F. novicida resulted in more rapid bacterial replication and dissemination leading to death within 96 h. Early containment of Delta mglA infection was partially dependent on myeloid differentiation factor 88 and interferon-gamma but did not require B or T cells. However, lymphocytes were necessary for subsequent bacterial clearance. Infection with Delta mglA elicited specific IgG1-predominant antibodies and variable interferon-gamma recall responses to wild type F. novicida. Inoculation of mice with aerosolized Delta mglA afforded no protection against a subsequent low-dose aerosol challenge with wild type F. novicida. These findings establish that inhalation of F. novicida Delta mglA results in replicative infection that elicits innate and adaptive immune responses but not protective immunity against invasive pneumonic tularemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539500      PMCID: PMC2657097          DOI: 10.1016/j.micinf.2008.04.008

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  31 in total

Review 1.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

2.  Francisella tularensis induces aberrant activation of pulmonary dendritic cells.

Authors:  Catharine M Bosio; Steven W Dow
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

3.  Modulation of biogenesis of the Francisella tularensis subsp. novicida-containing phagosome in quiescent human macrophages and its maturation into a phagolysosome upon activation by IFN-gamma.

Authors:  Marina Santic; Maelle Molmeret; Yousef Abu Kwaik
Journal:  Cell Microbiol       Date:  2005-07       Impact factor: 3.715

Review 4.  Tularemia as a biological weapon: medical and public health management.

Authors:  D T Dennis; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; M Layton; S R Lillibridge; J E McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

Review 5.  Will the enigma of Francisella tularensis virulence soon be solved?

Authors:  Richard W Titball; Anders Johansson; Mats Forsman
Journal:  Trends Microbiol       Date:  2003-03       Impact factor: 17.079

6.  Role of NK cells and gamma interferon in transplacental passage of Toxoplasma gondii in a mouse model of primary infection.

Authors:  Ahmed Abou-Bacar; Alexander W Pfaff; Sophie Georges; Valérie Letscher-Bru; Denis Filisetti; Odile Villard; Elisabeth Antoni; Jean-Paul Klein; Ermanno Candolfi
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia.

Authors:  Annalisa Lembo; Mark Pelletier; Ravi Iyer; Michele Timko; Jan C Dudda; T Eoin West; Christopher B Wilson; Adeline M Hajjar; Shawn J Skerrett
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

8.  Myeloid differentiation factor-88 (MyD88) is essential for control of primary in vivo Francisella tularensis LVS infection, but not for control of intra-macrophage bacterial replication.

Authors:  Carmen M Collazo; Alan Sher; Anda I Meierovics; Karen L Elkins
Journal:  Microbes Infect       Date:  2006-01-18       Impact factor: 2.700

9.  Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.

Authors:  Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee; J Wayne Conlan
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

10.  Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia.

Authors:  Michael A Pammit; Erin K Raulie; Crystal M Lauriano; Karl E Klose; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

View more
  16 in total

1.  Proteomic analysis of bronchoalveolar lavage fluid proteins from mice infected with Francisella tularensis ssp. novicida.

Authors:  Susan M Varnum; Bobbie-Jo M Webb-Robertson; Joel G Pounds; Ronald J Moore; Richard D Smith; Charles W Frevert; Shawn J Skerrett; David Wunschel
Journal:  J Proteome Res       Date:  2012-06-22       Impact factor: 4.466

2.  FTT0831c/FTL_0325 contributes to Francisella tularensis cell division, maintenance of cell shape, and structural integrity.

Authors:  Gregory T Robertson; Elizabeth Di Russo Case; Nicole Dobbs; Christine Ingle; Murat Balaban; Jean Celli; Michael V Norgard
Journal:  Infect Immun       Date:  2014-04-28       Impact factor: 3.441

3.  Genome-wide screen in Francisella novicida for genes required for pulmonary and systemic infection in mice.

Authors:  Petra S Kraemer; Allison Mitchell; Mark R Pelletier; Larry A Gallagher; Mike Wasnick; Laurence Rohmer; Mitchell J Brittnacher; Colin Manoil; Shawn J Skerett; Nina R Salama
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

Review 4.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

Review 5.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

Review 6.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11

7.  Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia.

Authors:  Annalisa Lembo; Mark Pelletier; Ravi Iyer; Michele Timko; Jan C Dudda; T Eoin West; Christopher B Wilson; Adeline M Hajjar; Shawn J Skerrett
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

Review 8.  Live attenuated tularemia vaccines: recent developments and future goals.

Authors:  Mark E Marohn; Eileen M Barry
Journal:  Vaccine       Date:  2013-06-10       Impact factor: 3.641

9.  Murine pulmonary infection and inflammation induced by inhalation of Burkholderia pseudomallei.

Authors:  T Eoin West; Nicolle D Myers; H Denny Liggitt; Shawn J Skerrett
Journal:  Int J Exp Pathol       Date:  2012-12       Impact factor: 1.925

10.  Differentiation of gram-negative bacterial aerosol exposure using detected markers in bronchial-alveolar lavage fluid.

Authors:  David Wunschel; Bobbie-Jo Webb-Robertson; Charles W Frevert; Shawn Skerrett; Nat Beagley; Alan Willse; Heather Colburn; Kathryn Antolick
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.